13F reference period
Q2 2026
Security Snapshot
Dianthus Therapeutics, Inc. /DE/ - Common Stock (DNTH) Institutional Ownership
CUSIP: 252828108
13F Institutional Holders and Ownership History from Q3 2023 to Q3 2026
Institutions Reporting
267
Shares (Excl. Options)
65.76M
Full value: 65,755,344 · shares · 30 Jun 2026Price
$97.48
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- DNTH on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 65,755,344
- Total 13F value
- $6,398,570,205
- Portfolio coverage rank
- 0.01%
- Share change
- +3,876,836
- Value change
- +$444,554,052
- Number of holders
- 267
- Shares outstanding
- 56,039,094
- SEC-reported price per share
- $85.40
- Insider filing price
- $85.40
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- DNTH - Dianthus Therapeutics, Inc. /DE/ - Common Stock is tracked under CUSIP 252828108.
- 267 institutions reported positions in Q2 2026.
- 15 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 239 to 267 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$5.14B
Full value: $5,141,754,510 · USD · 31 Mar 2026.$6.4B
Full value: $6,398,570,205 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 267 institutions filings for Q2 2026.
Security key
252828108
13F reference period
Q2 2026
13F holders
267
13D/G owners
15
CIK / CUSIP context first
Open Q2 2026 holders
DNTH full holder history
Dianthus Therapeutics, Inc. /DE/ SEC filings
Dianthus Therapeutics, Inc. /DE/ company facts
Dianthus Therapeutics, Inc. /DE/ insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 252828108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
15
Security
DNTH
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 12% | +71% | $650,429,955 | +$269,089,075 | 6,632,303 | +71% | T. Rowe Price Investment Management, Inc. | 31 Jul 2026 |
| FMR LLC | 15% | +7.1% | $234,944,605 | +$58,553,941 | 5,970,638 | +33% | FMR LLC | 30 Sep 2025 |
| BlackRock, Inc. | 6.4% | +26% | $341,584,350 | +$84,822,957 | 3,504,166 | +33% | BlackRock, Inc. | 30 Jun 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | 5.9% | +22% | $316,754,528 | +$62,186,089 | 3,229,882 | +24% | Wellington Management Group LLP | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.1% | $250,659,507 | 2,846,786 | Vanguard Capital Management | 30 Sep 2026 | |||
| RA CAPITAL MANAGEMENT, L.P. | 4.8% | -20% | $239,391,447 | 2,611,733 | 0% | RA Capital Management, L.P. | 31 Mar 2026 | |
| Fairmount Funds Management LLC | 4.9% | -50% | $72,191,285 | -$64,524,950 | 2,139,635 | -47% | Fairmount Funds Management LLC | 21 Nov 2025 |
| Avidity Partners Management LP | 4.9% | -50% | $70,995,168 | -$43,010,234 | 2,104,184 | -38% | Avidity Partners Management LP | 17 Nov 2025 |
| Octagon Capital Advisors LP | 3.6% | -42% | $178,431,497 | -$43,080,200 | 1,946,667 | -19% | Octagon Capital Advisors LP | 31 Mar 2026 |
| Sirenia Capital Management LP | 3.1% | -44% | $166,400,371 | -$108,011,454 | 1,696,751 | -39% | Sirenia Capital Management LP | 30 Jun 2026 |
| TCG Crossover GP II, LLC | 4.7% | $32,660,322 | 1,501,624 | TCG Crossover GP II, LLC | 31 Mar 2025 | |||
| BCLS Fund III Investments, LP | 3.1% | -55% | $51,780,350 | -$45,896,187 | 1,315,892 | -47% | BCLS Fund III Investments, LP | 30 Sep 2025 |
| Vestal Point Capital, LP | 3% | -70% | $46,433,000 | -$79,487,000 | 1,180,000 | -63% | Vestal Point Capital, LP | 30 Sep 2025 |
| Venrock Healthcare Capital Partners III, L.P. | 3.1% | $20,060,000 | 1,000,000 | Venrock Healthcare Capital Partners III, L.P. | 30 Jun 2025 | |||
| Point72 Asset Management, L.P. | 1.2% | -81% | $58,992,284 | -$214,307,954 | 643,599 | -78% | Point72 Asset Management, L.P. | 31 Mar 2026 |
As of 30 Jun 2026,
267
institutional investors reported holding
shares of
Dianthus Therapeutics, Inc. /DE/ - Common Stock (DNTH).
This represents
117%
of the company’s total
outstanding shares.
65.76M
Full value: 65,755,344 · shares · 30 Jun 202656.04M
Full value: 56,039,094 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
86%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 8,199,893 | +5.6% | 0.03% | $799,325,570 |
| BlackRock, Inc. | 7.4% | 4,123,822 | +30% | 0.01% | $401,990,169 |
| T. Rowe Price Investment Management, Inc. | 6.9% | 3,888,456 | +201% | 0.25% | $379,047,000 |
| WELLINGTON MANAGEMENT GROUP LLP | 5.8% | 3,229,882 | +24% | 0.05% | $314,848,897 |
| Fairmount Funds Management LLC | 4.5% | 2,537,191 | 0% | 16% | $247,325,379 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 4.5% | 2,514,946 | +119% | 0.02% | $245,158,000 |
| STATE STREET CORP | 4.2% | 2,357,440 | +69% | 0.01% | $229,798,634 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.9% | 2,159,568 | +6.3% | 0% | $210,514,689 |
| Avidity Partners Management LP | 3.8% | 2,104,184 | 0% | 33% | $205,115,856 |
| Octagon Capital Advisors LP | 3.3% | 1,841,667 | -5.4% | 16% | $179,525,699 |
| TCG Crossover Management, LLC | 3% | 1,676,624 | 0% | 3.9% | $163,437,308 |
| FRED ALGER MANAGEMENT, LLC | 2.3% | 1,302,493 | +12% | 0.42% | $126,967,018 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 1,258,502 | +37% | 0.01% | $122,696,604 |
| Venrock Adviser, LLC | 2.1% | 1,180,000 | 0% | 3.5% | $115,026,400 |
| UBS Group AG | 2% | 1,140,260 | +46% | 0.02% | $111,152,545 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 2% | 1,125,313 | +10% | 1.1% | $109,695,511 |
| JENNISON ASSOCIATES LLC | 1.8% | 1,021,763 | +111% | 0.06% | $99,601,453 |
| Polar Capital Holdings Plc | 1.8% | 1,018,726 | -5.3% | 0.28% | $99,305,410 |
| CITADEL ADVISORS LLC | 1.7% | 974,911 | -39% | 0.05% | $95,034,324 |
| FRANKLIN RESOURCES INC | 1.7% | 968,983 | +0.08% | 0.02% | $94,456,440 |
| BAKER BROS. ADVISORS LP | 1.5% | 852,164 | 0% | 0.42% | $83,068,947 |
| ALLIANCEBERNSTEIN L.P. | 1.5% | 834,150 | 0% | 0.03% | $70,001,868 |
| Logos Global Management LP | 1.4% | 800,000 | +100% | 3.4% | $77,984,000 |
| Cormorant Asset Management, LP | 1.3% | 750,000 | -21% | 3.8% | $73,110,000 |
| BRAIDWELL LP | 1.1% | 594,562 | -34% | 2.1% | $57,957,904 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
13
Headline period
Q2 2026
Rows shown
1-13 of 13
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 929,118 | $81,808,909 | +$40,197,902 | $88.05 | 34 |
| 2026 Q2 | 65,755,344 | $6,398,570,205 | +$444,554,052 | $97.48 | 267 |
| 2026 Q1 | 61,271,372 | $5,141,754,510 | +$1,107,843,049 | $83.92 | 239 |
| 2025 Q4 | 49,121,649 | $2,024,311,315 | +$67,678,158 | $41.21 | 167 |
| 2025 Q3 | 46,828,772 | $1,842,663,442 | +$358,133,968 | $39.35 | 140 |
| 2025 Q2 | 39,106,709 | $728,558,630 | +$24,440,177 | $18.63 | 101 |
| 2025 Q1 | 37,715,319 | $685,461,303 | +$43,246,773 | $18.14 | 97 |
| 2024 Q4 | 35,126,689 | $765,706,199 | +$63,092,353 | $21.80 | 94 |
| 2024 Q3 | 31,364,805 | $858,714,506 | +$44,837,092 | $27.38 | 90 |
| 2024 Q2 | 29,702,499 | $768,778,734 | +$87,583,327 | $25.88 | 74 |
| 2024 Q1 | 26,075,021 | $782,250,559 | +$479,966,613 | $30.00 | 75 |
| 2023 Q4 | 10,291,119 | $106,507,945 | +$518,588 | $10.40 | 38 |
| 2023 Q3 | 10,072,640 | $136,328,208 | +$136,328,208 | $13.67 | 30 |